Eisai company profile

4523 · TSE · JPY

Compare Eisai
¥5,280.00Change from previous close: +1.81%Absolute change: +¥94.00

Close · November 16, 2026

Company profile

Eisai has 10,543 employees and is headquartered in Tokyo, Japan.

Eisai is known mainly through Lenvima, LEQEMBI and Dayvigo, the products of a Japanese pharmaceutical company that researches, develops, manufactures and sells drugs in Japan and abroad. Its focus lies in neurology and oncology, and its range includes prescription drugs and over-the-counter medicines. LEQEMBI is a humanized IgG1 monoclonal antibody against amyloid-beta protofibrils, Lenvima is a multi-kinase inhibitor involved in tumor angiogenesis, and Dayvigo is a novel small molecule compound. Sales extend to Europe, the Middle East, Africa, Russia, Oceania, the Americas, China, East Asia and the Global South.

In the fiscal year ended March 2026, Eisai posted revenue of 825.4 billion yen, up 4.6% from the previous year, and net income of 38.6 billion yen. The company employed 10,543 people and is headquartered in Tokyo, where it was incorporated in 1941. It was formerly known as Nihon Eisai and took its current name in 1955.

Company facts

Industry
Drug Manufacturers - Specialty & Generic
Country
Japan
Headquarters
4-6-10 Koishikawa, 112-8088, Tokyo
Employees
10,543
Chief executive
Haruo Naito
Founded
1941
Fiscal year
April - March
Listing
4523 · TSE
Indices
Nikkei 225
Currency
JPY
ISIN
JP3160400002

Eisai and its competitors

The most similar companies by business and size

CompanyCountryMarket capEmployeesOperating marginP/E (trailing 12 months)
Eisai4523Japan$9.14B10,5436.7%33.3
Kyowa Kirin4151Japan$8.46B5,16121.8%16.6
CiplaCIPLAIndia$11.93B31,36913.0%38.8
Zhejiang NHU002001China$12.3B11,50833.8%10.9
Zydus LifesciencesZYDUSLIFEIndia$12.59B29,98017.2%28.4
Laurus LabsLAURUSLABSIndia$13.9B7,05924.1%97.8

Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.

Compare Eisai with its competitors